Nov 9 (Reuters) - Dynavax Technologies Corp’s twice-rejected hepatitis B vaccine was approved by the U.S. Food and Drug Administration on Thursday, marking the drug developer’s first regulatory approval.
The two-dose vaccine, Heplisav-B, is designed to enhance the body’s immune response to the hepatitis B virus in adults aged 18 years and older.
A panel of independent advisers to the FDA in July voted in favor of and recommended approving the vaccine. (Reporting by Divya Grover in Bengaluru; Editing by Savio D’Souza)
Our Standards: The Thomson Reuters Trust Principles.